Krystal Biotech (KRYS) Expected to Announce Quarterly Earnings on Tuesday

Krystal Biotech (NASDAQ:KRYS) is expected to be announcing its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of $1.35 per share and revenue of $98.66 million for the quarter.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same period last year, the business earned $0.30 earnings per share. Krystal Biotech’s revenue was up 116.4% compared to the same quarter last year. On average, analysts expect Krystal Biotech to post $6 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $166.16 on Friday. The company’s 50 day simple moving average is $174.92 and its two-hundred day simple moving average is $171.25. Krystal Biotech has a 1 year low of $141.72 and a 1 year high of $219.34. The stock has a market capitalization of $4.80 billion, a PE ratio of 55.57 and a beta of 0.79.

Insider Activity

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup boosted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. HC Wainwright raised their target price on shares of Krystal Biotech from $221.00 to $240.00 and gave the company a “buy” rating in a research note on Monday, April 28th. Chardan Capital boosted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Finally, Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $222.71.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).